Get the Stockscreener App
1.87
2.09%
-0.04
After Hours:
1.87
Cabaletta Bio Inc stock is traded at $1.87, with a volume of 1.03M.
It is down -2.09% in the last 24 hours and up +41.67% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$1.91
Open:
$1.9
24h Volume:
1.03M
Relative Volume:
0.84
Market Cap:
$94.88M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.1265
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+6.86%
1M Performance:
+41.67%
6M Performance:
-51.05%
1Y Performance:
-81.17%
1-Day Range:
$1.815
$1.99
1-Week Range:
$1.68
$1.99
52-Week Range:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.87 | 88.80M | 0 | -67.68M | -54.24M | -1.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Northern Trust Corp Sells 5,849 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MyChesCo
Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cabaletta Bio Showcases First-Ever Curative Autoimmune Cell Therapies at Major Jefferies Conference - Stock Titan
D. E. Shaw & Co. Inc. Sells 17,359 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones - MSN
Point72 Asset Management L.P. Acquires 598,607 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Announces Quarterly Earnings Results - MarketBeat
Cantor Fitzgerald Predicts Weaker Earnings for Cabaletta Bio - MarketBeat
Cabaletta Bio Reprices Stock Options to Motivate Staff - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Raiffeisen Bank International AG Invests $493,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Cantor Fitzgerald Estimates Cabaletta Bio FY2025 Earnings - Defense World
Cabaletta Bio announces option repricing for key personnel By Investing.com - Investing.com India
CABA FRAUD ALERT: Hagens Berman, National Trial Attorneys, Encourages Cabaletta Bio (CABA) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Cabaletta Bio announces option repricing for key personnel - Investing.com
Cabaletta Bio (CABA) Projected to Post Earnings on Wednesday - MarketBeat
Citigroup Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $13.00 - Defense World
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - Defense World
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CABA Stock News: Citigroup Lowers Price Target but Maintains Buy - GuruFocus
CABA: Guggenheim Raises Price Target for Cabaletta Bio to $25 | CABA Stock News - GuruFocus
UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating - marketscreener.com
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - simplywall.st
Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating - TipRanks
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rat - GuruFocus
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rating | CABA Stock News - GuruFocus
Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission - marketscreener.com
41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Stifel Financial Corp - Defense World
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Asianet Newsable
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Ratin - GuruFocus
Fred Alger Management LLC Sells 1,803,170 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Rating | CABA Stock News - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $2 - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $25 | CABA Stock News - GuruFocus
Cabaletta Bio (CABA) Targets 2027 for Rese-cel BLA Submission | - GuruFocus
Cabaletta Bio Inc (CABA) Reports Q1 EPS Miss at -0.64, No Revenue Recorded - GuruFocus
Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts - marketscreener.com
Cabaletta Bio Announces 2027 BLA Plans for Rese-cel - TipRanks
Cabaletta Bio, Inc. SEC 10-Q Report - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent ... - Eagle-Tribune
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - Yahoo Finance
Barclays PLC Boosts Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday - Defense World
Wells Fargo & Company MN Purchases 16,250 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):